STERIS plc $STE Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its stake in STERIS plc (NYSE:STE) by 160.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 48,846 shares of the medical equipment provider’s stock after purchasing an additional 30,104 shares during the quarter. Assenagon Asset Management S.A.’s holdings in STERIS were worth $10,801,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Trust Co. of Vermont raised its holdings in shares of STERIS by 30.2% in the fourth quarter. Trust Co. of Vermont now owns 164 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 38 shares during the last quarter. Bailard Inc. lifted its position in STERIS by 3.5% during the 4th quarter. Bailard Inc. now owns 1,118 shares of the medical equipment provider’s stock worth $283,000 after acquiring an additional 38 shares during the period. Magnolia Capital Advisors LLC grew its stake in STERIS by 1.2% during the 3rd quarter. Magnolia Capital Advisors LLC now owns 3,588 shares of the medical equipment provider’s stock valued at $888,000 after purchasing an additional 41 shares during the last quarter. Geneos Wealth Management Inc. grew its stake in STERIS by 34.9% during the 2nd quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 45 shares during the last quarter. Finally, Ascent Group LLC grew its stake in STERIS by 4.9% during the 4th quarter. Ascent Group LLC now owns 1,009 shares of the medical equipment provider’s stock valued at $256,000 after purchasing an additional 47 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Weiss Ratings downgraded STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Piper Sandler restated an “overweight” rating and issued a $270.00 target price on shares of STERIS in a research note on Thursday, May 21st. Finally, KeyCorp dropped their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $278.00.

STERIS Price Performance

Shares of NYSE STE opened at $215.59 on Friday. The firm has a 50-day simple moving average of $212.77 and a 200-day simple moving average of $233.29. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $21.01 billion, a price-to-earnings ratio of 27.19 and a beta of 0.93. STERIS plc has a 52 week low of $195.14 and a 52 week high of $269.44.

STERIS (NYSE:STE) last released its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same period last year, the firm posted $2.74 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, equities analysts predict that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 26th. Investors of record on Monday, June 8th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

Insider Activity at STERIS

In other news, VP John Adam Zangerle sold 1,419 shares of STERIS stock in a transaction on Monday, June 15th. The stock was sold at an average price of $209.28, for a total value of $296,968.32. Following the completion of the sale, the vice president directly owned 35,259 shares of the company’s stock, valued at approximately $7,379,003.52. The trade was a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel A. Carestio sold 1,374 shares of STERIS stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $212.00, for a total value of $291,288.00. Following the completion of the transaction, the chief executive officer directly owned 63,647 shares of the company’s stock, valued at approximately $13,493,164. This represents a 2.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 7,328 shares of company stock worth $1,554,051. Insiders own 1.12% of the company’s stock.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.